Novartis agreed to acquire Synnovation’s Pikavation subsidiary and its SNV4818 PI3Kα inhibitor program for $2 billion up front, with up to $1 billion in milestones. SNV4818 is a pan‑mutant selective PI3Kα inhibitor currently in Phase II, positioned for HR+/HER2‑ metastatic breast cancer and other solid tumors. Novartis said the asset complements its precision oncology strategy and could slot alongside endocrine and CDK inhibitor combinations. Synnovation will retain other R&D assets while Novartis takes over global development and commercialization, aiming to accelerate clinical work with its global capabilities.